Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. According to the traditional view, primary liver cancer is an immunosuppressive tumor. Studies have shown that tumor-specific cytotoxic T cells in primary liver cancer are accompanied by high expression of inhibitory immune checkpoints such as CTLA4, PD-L1, and TIM3, which makes T cells unable to effectively recognize tumor cells and lead to immune escape. Immunotherapy provides a new strategy for the treatment of HCC. However, the response rate of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, in HCC is limited, and the underlying mechanism remains to be explored. Therefore, it is urgent to figure out the potential causes of immune escape of HCC and eliminate them as much as possible.
The wide use of next-generation sequencing (NGS)-based diagnostic tests, such as RNA-seq and WES, resulted in the identification of novel candidate biomarkers. Immune-related clinical indicators have also played an important role in the prognosis for patients with hepatocellular carcinoma. Immune clustering has also been shown to have prognostic significance and implications on the heterogenicity of patients’ response to immunotherapy.
In this Research Topic, we would like to bring together recent advances studying different immunophenotype patterns to explain heterogeneous prognosis among patients with hepatocellular carcinoma. Studies exploring indicators to predict or evaluate the efficacy of immunotherapy in hepatocellular carcinoma patients are also welcome. Additionally, we will combine with clinical practice and develop an immune-related clinical marker model to predict the prognosis in patients with hepatocellular carcinoma. We welcome submissions of Original Research and Review articles focusing on but not limited to the following aspects:
• Different immunophenotype as biomarkers in the prognosis in hepatocellular carcinoma, (Article)
• Baseline immune-related clinical indicators in the prognosis of hepatocellular carcinoma, (Article)
• Neoantigen based immunotherapy in hepatocellular carcinoma,( Article or Review)
• Biomarkers to predict the efficacy of immunotherapy in hepatocellular carcinoma, (Article)
Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. According to the traditional view, primary liver cancer is an immunosuppressive tumor. Studies have shown that tumor-specific cytotoxic T cells in primary liver cancer are accompanied by high expression of inhibitory immune checkpoints such as CTLA4, PD-L1, and TIM3, which makes T cells unable to effectively recognize tumor cells and lead to immune escape. Immunotherapy provides a new strategy for the treatment of HCC. However, the response rate of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, in HCC is limited, and the underlying mechanism remains to be explored. Therefore, it is urgent to figure out the potential causes of immune escape of HCC and eliminate them as much as possible.
The wide use of next-generation sequencing (NGS)-based diagnostic tests, such as RNA-seq and WES, resulted in the identification of novel candidate biomarkers. Immune-related clinical indicators have also played an important role in the prognosis for patients with hepatocellular carcinoma. Immune clustering has also been shown to have prognostic significance and implications on the heterogenicity of patients’ response to immunotherapy.
In this Research Topic, we would like to bring together recent advances studying different immunophenotype patterns to explain heterogeneous prognosis among patients with hepatocellular carcinoma. Studies exploring indicators to predict or evaluate the efficacy of immunotherapy in hepatocellular carcinoma patients are also welcome. Additionally, we will combine with clinical practice and develop an immune-related clinical marker model to predict the prognosis in patients with hepatocellular carcinoma. We welcome submissions of Original Research and Review articles focusing on but not limited to the following aspects:
• Different immunophenotype as biomarkers in the prognosis in hepatocellular carcinoma, (Article)
• Baseline immune-related clinical indicators in the prognosis of hepatocellular carcinoma, (Article)
• Neoantigen based immunotherapy in hepatocellular carcinoma,( Article or Review)
• Biomarkers to predict the efficacy of immunotherapy in hepatocellular carcinoma, (Article)
Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Oncology.
